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Novel Inhibitors of Indoleamine 2,3-Dioxygenase (IDO),
a Target for Anti-Cancer Immunotherapy
Introduction. Immunotherapy is a promising novel 
strategy for cancer therapy. However, this approach 
showed a limited efficacy in vivo because cancer cells can 
develop mechanisms allowing tumors to resist or escape 
immune rejection.
IDO (EC 1.13.11.52 ), a heme dioxygenase, is expressed 
constitutively in many human tumors and its role in a 
tumoral immune resistance mechanism has been proved,1 
justifying the interest in IDO inhibitors.2
Aim of the Work. We sought to develop a novel series of 
IDO inhibitors starting with a virtual screening of a 
database of commercially-available compounds.
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Virtual screening. Based on recent results such as 
structural findings3 and rational design of IDO 
inhibitors,4 we applied virtual screening of the 
ZINC database (http://zinc.docking.org) for the 
discovery of new inhibitors (Figure 1). The most 
promising candidates were purchased and tested in 
vitro. 1-(1H-Indol-2-yl)-2-pyridin-3-yl-ethanone (7a;
IC50 = 65 µM ) was selected for pharmaco-
modulation (Schemes 1 and 2 and Table 1).
Figure 1.
IDO Virtual screening flowchart. (i) fragment library,
(ii) goldscore > 50, (iii) Cscore ≥ 4, (iv) visual analysis
and selection, (v) really commercially-available.
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Scheme 1. General synthetic scheme for indol-2-yl ethanones.5 Reagents and conditions:
(i), LDA, THF / hexanes, -78 to 0°C, 1 h; (ii) THF / hexanes, 0°C to rt, 16-24 h; (iii) SOCl2, ∆,
15 min; (iv), hexane, 200°C (µW), 5 min; (v), N3CH2CO2Et, NaOEt, EtOH, -10 to 4°C, 1.5 - 20 h;
(vi), MeI, K2CO3, DMF, 80°C, 5 days; (vii), AlCl3, CH2Cl2, 0°C to r. t, 24 h; (viii), HCO2NH4,
Pd black, MeOH, r. t, 1 h; (ix) H2 (1 atm), 3% Pd/C, EtOH, r. t, 45 min; (x) PhB(OH)2, Pd(PPh3)4,
K2CO3, EtOH/toluene 1/1, ∆, 20 h.
Scheme 2. Synthesis of compounds bearing
different linker groups. Reagents and 
conditions: (i) HCO2NH4, Pd black, 
MeOH, r. t, 3 days; 
(ii), H2NNH2, KOH, (CH2OH)2, µW, 1h then 
aq. NH4Cl;
(iii), NH2OH
.HCl, pyridine, EtOH, µW (120°C),
30 min; (iv), SOCl2, ∆, 15 min then
3-aminopyridine, DIPEA, THF, 0°C -> r. t, 30 
min.
Synthesis
Figure 2. Docking of
compound 7a inside
the IDO active site 
showing
interaction of the 
carbonyl oxygen
with the heme iron
Table 1. Biological evaluation
compound R R'
enzymatic assay 
IC50 (µM)
cell assay inh. % 
@ 20 µM
7a H H 65 13
7b 3-Br H >100 NI
7c 4-F H >100 12
7d 4-OCH3 H 58 NI
7e 4-OH H 83 NI
7f 5-F H 36 24
7g 5-Cl H 25 24
7h 5-Br H 18 NI
7i 5-CH3 H 87 21
7j 5-OCH3 H 49 -
7k 5-NO2 H >100 NI
7l 5-Ph H 96 NI
7m 5-OCF3 H 13 12
7o 5-OH H 37 NI
7p 6-F H 43 NI
7q 7-OCH3 H 82 -
7r 4-OBn, 5-OCH3 H >100 NI
7s 4-OH, 5-OCH3 H 63 11
7t 4,6-diCl H >100 NI
7u 4,6-di(OCH3) H 45 toxic
7v H CH3 >100 NI
8a H H 37 10
9a H H >100 NI
10a H H 26 NI
11a H H 29 NI
12a H CH3 34 NI
13 H H >100 NI
14 H H >100 NI
15 H H >100 25
16 H - 94 NI
NI = no inhibition
Conclusion. The synthesis and SAR of a novel series of IDO inhibitors are 
described.6 Starting from the lead compound 7a (IC50 = 65 µM) identified through a 
virtual screening procedure, up to a 5-fold improvement in in vitro potency could be 
achieved by introducing small substituents in the 5- and 6-positions of the indole 
nucleus. Most modifications of the aromatic moieties are tolerated. On the contrary, 
the presence of an iron chelating group on the linker seems to be mandatory, as 
corroborated by the docking experiments (Fig. 2). A number of compounds are also 
moderately active in the in vivo assay, thus opening possibilities for further 
pharmacological evaluation.
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